Sex and age difference in risk factor distribution, trend, and long-term outcome of patients undergoing isolated coronary artery bypass graft surgery.


Journal

BMC cardiovascular disorders
ISSN: 1471-2261
Titre abrégé: BMC Cardiovasc Disord
Pays: England
ID NLM: 100968539

Informations de publication

Date de publication:
23 09 2021
Historique:
received: 13 06 2021
accepted: 20 09 2021
entrez: 24 9 2021
pubmed: 25 9 2021
medline: 18 1 2022
Statut: epublish

Résumé

Preoperative coronary artery disease risk factors (CADRFs) distribution and pattern may also have an important role in determining major adverse cardiovascular events (MACEs). In this study, we aimed to evaluate the CADRFs distribution and trend over 10 years and also the long-term outcome of CABG in different age-sex categories. In this registry-based serial cross-sectional study, we enrolled 24,328 patients who underwent isolated CABG and evaluated the prevalence of CADRFs according to sex and age. We used inverse probability weighting (IPW) to compare survival and MACE between the sexes. We also used Cox regression to determine each CADRFs effect on survival and MACEs. In general, DLP (56.00%), HTN (53.10%), DM (38.40%), and positive family history (38.30%) were the most frequent risk factors in all patients. Prevalence of HTN, DLP, DM, obesity, and positive family history were all higher in women, all statistically significant. The median follow-up duration was 78.1 months (76.31-79.87 months). After inverse probability weighting (to balance risk factors and comorbidities), men had lower MACEs during follow-up (HR 0.72; 95% CI 0.57-0.91; P value 0.006) and there was no significant difference in survival between sexes. DM and HTN were associated with higher mortality and MACEs in both sexes. Although DLP is still the most frequent CADRF among the CABG population, the level of LDL and TG is decreasing. Women experience higher MACE post CABG. Therefore, health care providers and legislators must pay greater attention to female population CADRFs and ways to prevent them at different levels.

Sections du résumé

BACKGROUND
Preoperative coronary artery disease risk factors (CADRFs) distribution and pattern may also have an important role in determining major adverse cardiovascular events (MACEs). In this study, we aimed to evaluate the CADRFs distribution and trend over 10 years and also the long-term outcome of CABG in different age-sex categories.
METHOD
In this registry-based serial cross-sectional study, we enrolled 24,328 patients who underwent isolated CABG and evaluated the prevalence of CADRFs according to sex and age. We used inverse probability weighting (IPW) to compare survival and MACE between the sexes. We also used Cox regression to determine each CADRFs effect on survival and MACEs.
RESULTS
In general, DLP (56.00%), HTN (53.10%), DM (38.40%), and positive family history (38.30%) were the most frequent risk factors in all patients. Prevalence of HTN, DLP, DM, obesity, and positive family history were all higher in women, all statistically significant. The median follow-up duration was 78.1 months (76.31-79.87 months). After inverse probability weighting (to balance risk factors and comorbidities), men had lower MACEs during follow-up (HR 0.72; 95% CI 0.57-0.91; P value 0.006) and there was no significant difference in survival between sexes. DM and HTN were associated with higher mortality and MACEs in both sexes.
CONCLUSION
Although DLP is still the most frequent CADRF among the CABG population, the level of LDL and TG is decreasing. Women experience higher MACE post CABG. Therefore, health care providers and legislators must pay greater attention to female population CADRFs and ways to prevent them at different levels.

Identifiants

pubmed: 34556032
doi: 10.1186/s12872-021-02273-2
pii: 10.1186/s12872-021-02273-2
pmc: PMC8461921
doi:

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

460

Informations de copyright

© 2021. The Author(s).

Références

J Opioid Manag. 2009 Nov-Dec;5(6):365-72
pubmed: 20073410
Coron Artery Dis. 2018 Dec;29(8):657-662
pubmed: 30308587
Eur J Prev Cardiol. 2020 Dec;27(19):2308-2310
pubmed: 31856603
J Thorac Cardiovasc Surg. 2012 Feb;143(2):273-81
pubmed: 22248680
J Am Coll Cardiol. 2015 Nov 3;66(18):1949-1957
pubmed: 26515996
Int Heart J. 2017 Aug 3;58(4):475-480
pubmed: 28717115
Eur J Cardiothorac Surg. 2020 May 1;57(5):986-993
pubmed: 31819982
Pharmacotherapy. 2012 Mar;32(3):222-33
pubmed: 22392455
JAMA Surg. 2015 Apr;150(4):308-15
pubmed: 25671647
Eur Cardiol. 2017 Aug;12(1):10-13
pubmed: 30416543
Vasc Health Risk Manag. 2019 May 01;15:89-100
pubmed: 31118651
Sci Rep. 2017 Oct 18;7(1):13461
pubmed: 29044139
Biomedicine (Taipei). 2020 Dec 01;10(4):23-28
pubmed: 33854931
Lancet Diabetes Endocrinol. 2019 Nov;7(11):866-879
pubmed: 31422063
J Am Heart Assoc. 2019 Jul 16;8(14):e012178
pubmed: 31280642
Eur Heart J. 2018 Aug 1;39(29):2695-2696
pubmed: 30289514
Biomed Res Int. 2017;2017:9829487
pubmed: 29423414
Am J Cardiol. 1976 Jul;38(1):46-51
pubmed: 132862
Eur J Prev Cardiol. 2020 Dec;27(18):1996-2003
pubmed: 32673508
Circulation. 1994 Jul;90(1):583-612
pubmed: 8026046
J Thorac Dis. 2018 Mar;10(3):1960-1967
pubmed: 29707352
Atherosclerosis. 2015 Jul;241(1):284-8
pubmed: 25731671
Eur J Cardiothorac Surg. 2010 May;37(5):1068-74
pubmed: 20036136
Sci Rep. 2019 Jun 12;9(1):8567
pubmed: 31189989
Nutrition. 2020 Apr;72:110696
pubmed: 32007807
Addict Health. 2013 Summer-Autumn;5(3-4):140-53
pubmed: 24494171
Eur J Cardiothorac Surg. 2008 Aug;34(2):370-5
pubmed: 18539474
Indian Heart J. 2017 Jul - Aug;69(4):532-538
pubmed: 28822527
J Thorac Cardiovasc Surg. 2014 May;147(5):1517-23
pubmed: 23870152
Am Heart J. 2004 Jul;148(1):7-15
pubmed: 15215786
Sci Rep. 2020 Jul 16;10(1):11724
pubmed: 32678170
Lancet. 2004 Sep 11-17;364(9438):937-52
pubmed: 15364185
Circulation. 2016 Aug 9;134(6):441-50
pubmed: 27502908
Open Heart. 2020 Mar 17;7(1):e001163
pubmed: 32206316

Auteurs

Babak Sattartabar (B)

Department of Cardiology, Tehran Heart Center, Tehran University of Medical Sciences, North Kargar Ave., 1411713138, Tehran, Iran.
Research Department, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.

Ali Ajam (A)

Students' Scientific Research Center (SSRC), Tehran University of Medical Sciences, Tehran, Iran.

Mina Pashang (M)

Department of Cardiology, Tehran Heart Center, Tehran University of Medical Sciences, North Kargar Ave., 1411713138, Tehran, Iran.
Research Department, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.

Arash Jalali (A)

Department of Cardiology, Tehran Heart Center, Tehran University of Medical Sciences, North Kargar Ave., 1411713138, Tehran, Iran.
Research Department, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.

Saeed Sadeghian (S)

Department of Cardiology, Tehran Heart Center, Tehran University of Medical Sciences, North Kargar Ave., 1411713138, Tehran, Iran.
Research Department, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.

Hamideh Mortazavi (H)

Department of Cardiology, Tehran Heart Center, Tehran University of Medical Sciences, North Kargar Ave., 1411713138, Tehran, Iran.
Research Department, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.

Soheil Mansourian (S)

Department of Cardiac Surgery, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.

Jamshid Bagheri (J)

Department of Cardiac Surgery, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.

Abbas-Ali Karimi (AA)

Department of Cardiac Surgery, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.

Kaveh Hosseini (K)

Department of Cardiology, Tehran Heart Center, Tehran University of Medical Sciences, North Kargar Ave., 1411713138, Tehran, Iran. Kaveh_hosseini130@yahoo.com.
Research Department, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran. Kaveh_hosseini130@yahoo.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH